Skip to main content Skip to navigation
BV510 Mouse Anti-Human GPR56
Product Details
Down Arrow Up Arrow

BD OptiBuild™
G protein-coupled receptor 56; ADGRG1; BFPP; BPPR; TM7LN4; TM7XN1; testicular tissue protein Li 77
Human (Tested in Development)
Mouse BALB/c IgG1, κ
Human GPR56 Recombinant Protein
Flow cytometry (Qualified)
0.2 mg/ml
Aqueous buffered solution containing ≤0.09% sodium azide.

Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation).  When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application.

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

Product Notices

  1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  2. Researchers should determine the optimal concentration of this reagent for their individual applications.
  3. An isotype control should be used at the same concentration as the antibody of interest.
  4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at
  6. Please refer to for technical protocols.
  7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  8. Please refer to to access safety data sheets (SDS).
  9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
752702 Rev. 1
Antibody Details
Down Arrow Up Arrow

The CG4.rMab is a recombinant monoclonal antibody that was derived from CG4 hybridoma cells. The CG4.rMab specifically binds to human G-protein coupled receptor 56 (GPR56) like the conventional CG4 antibody and performs like the CG4 antibody when used to stain cells and analyze them by flow cytometry. GPR56 is also known as adhesion G-protein coupled receptor G1 (ADGRG1), or TM7XN1. GPR56 is a ~15kDa G protein-coupled receptor encoded by ADGRG1 which belongs to the adhesion-GPCR family that comprises 33 members in human. The extracellular region contains a mucin-like domain followed by a membrane proximal GPCR-autoproteolysis inducing (GAIN) domain, seven transmembrane regions and a cytoplasmic tail. The constitutive self-cleavage at the proteolytic site gives rise to a membrane spanning (C-terminal fragment or CTF) and an extracellular (N-terminal fragment or NTF) subunit that remain noncovalently bound, leading to the expression of a heterodimeric receptor at the cell surface. GPR56 is widely expressed with the highest levels of messenger found in the brain, heart, and thyroid gland. Recently, GPR56 was found to be variably expressed on platelets, cytotoxic NK cells and T lymphocytes including CD4+, CD8+, and γδ T cells. It was shown that GPR56 functions as an inhibitory receptor on NK cells through interaction with CD81. While GPR56 NTF associates with Tissue transglutaminase 2 and Collagen III (α-1), GPR56 CTF can recruit Gα proteins leading to the activation of mTOR and RhoA signaling pathways. GPR56 has been implicated in cell-cell interactions, adhesion, migration, and regulation of cell proliferation and survival of various cell types. New evidence also shows a role of GPR56 in tumor progression. Recently, the CG4 antibody was found to activate GPR56 in melanoma cells leading to an increase of IL-6 secretion, in a CD9/CD81-dependent manner.

The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser.

752702 Rev. 1
Format Details
Down Arrow Up Arrow
The BD Horizon Brilliant Violet™ 510 (BV510) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye with an excitation maximum (Ex Max) at 327-nm / 405-nm and an emission maximum (Em Max) at 512-nm. BV510, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 510-nm (e.g., a 525/50 bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Violet 405 nm
327 nm, 405 nm
512 nm
752702 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (6)

  1. Della Chiesa M, Falco M, Parolini S, et al. GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues.. Int Immunol. 2010; 22(2):91-100. (Biology: Flow cytometry). View Reference
  2. Liu M, Parker RM, Darby K, et al. GPR56, a novel secretin-like human G-protein-coupled receptor gene.. Genomics. 1999; 55(3):296-305. (Biology). View Reference
  3. Pabst C, Bergeron A, Lavallée VP, et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo.. Blood. 2016; 127(16):2018-27. (Clone-specific: Flow cytometry). View Reference
  4. Peng YM, van de Garde MD, Cheng KF, et al. Specific expression of GPR56 by human cytotoxic lymphocytes.. J Leukoc Biol. 2011; 90(4):735-40. (Immunogen: Flow cytometry). View Reference
  5. Piao X, Hill RS, Bodell A, et al. G protein-coupled receptor-dependent development of human frontal cortex.. Science. 2004; 303(5666):2033-6. (Biology). View Reference
  6. Rao TN, Marks-Bluth J, Sullivan J, et al. High-level Gpr56 expression is dispensable for the maintenance and function of hematopoietic stem and progenitor cells in mice.. Stem Cell Res. 2015; 14(3):307-22. (Clone-specific: Flow cytometry). View Reference
View All (6) View Less
752702 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.